We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Graft Versus Host Disease [GvHD] Treatment Market Insights, 2021-2031

Acute Graft Versus Host Disease [GvHD] Treatment Market (Drug Class: Corticosteroids, Immunosuppressive Agents, Biological Therapy, Kinase Inhibitors, Monoclonal Antibody, Mesenchymal Stem Cell [MSC], and Others; Route of Administration: Oral, Topical, and Intravenous; and Distributing Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Ruxolitinib Gains Recognition for At-home Treatment amid COVID-19 Crisis

In response to the public health emergency posed by the COVID-19 pandemic, National Health Service (NHS) England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with high risk of coronavirus. This has led to awareness about ruxolitinib, which is found to be effective in treating acute graft versus host disease (GvHD) patients who have not responded to steroids. Ruxolitinib is a tablet that can be consumed at home, which eliminates the need for a patient to visit hospital frequently and reduce the risk of contracting COVID-19.

Companies in the acute graft versus host disease (GvHD) treatment market are increasing their output capacities and maintaining steady supply for ruxolitinib as an alternative treatment option, which is reducing the need to attend hospital unless adverse events occur.

These factors are anticipated to drive the acute graft versus host disease (GvHD) treatment market during the forecast period.

acute graft versus host disease (gvhd) treatment market infographic

To know the scope of our report Get a Sample on Acute Graft Versus Host Disease [GvHD] Treatment Market

Corticosteroids Associated with Adverse Effects, Dismal Patient Outcomes

Clinically significant GvHD occurs frequently in spite of prophylaxis, which has led to the demand for corticosteroids as the mainstay of frontline therapy. However, in many cases, these drugs can have severe adverse effects and outcomes are dismal in patients who historically have had limited treatment options. Such findings are affecting the growth of the global acute graft versus host disease (GvHD) treatment market. Hence, companies in the acute graft versus host disease (GvHD) treatment market are boosting their R&D capabilities to successfully manufacture drugs that can be administered in a multicenter environment.

Get a glimpse of the in-depth analysis through our Report Brochure

Ruxolitinib Helps Overcome Steroid Resistance Found in GvHD Patients

Steroid resistance has been found in GvHD patients. This condition is difficult to treat and associated with a high mortality rate. In order to overcome these issues, companies in the acute graft versus host disease (GvHD) treatment market are boosting their output capacities for Ruxolitinib. This tablet holds promising potential as a treatment option for patients with steroid-refractory aGvHD after allogeneic hematopoietic stem cell transplantation.

Ruxolitinib tablet works by blocking the action of enzymes known as Janus kinases (JAKs) that are involved in the production and growth of blood cells & immune function. By blocking JAKs, ruxolitinib reduces the abnormal production of blood cells, which helps to reduce the symptoms of GvHD. This tablet helps to address the side effects linked with the consumption of steroids.

Manufacturers Increase Research in Orphan Drugs to Prevent GI Diseases

The gastrointestinal damage is a leading cause of death in patients with acute GvHD. The clinical stage biopharmaceutical company VectivBio Holding AG is gaining cognizance about this condition and has received the FDA orphan drug designation for apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases for the prevention of aGVHD. Companies in the acute graft versus host disease (GvHD) treatment market are gaining knowledge about such drug innovations and increasing their research capabilities.

Preclinical and clinical studies evaluating apraglutide & GLP-2 analogs in aGvHD indicate that apraglutide’s regenerative and anti-inflammatory effects on the GI tract may help to significantly reduce morbidity and mortality in patients suffering from intestinal GvHD.

acute graft versus host disease (gvhd) treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The ruxolitinib tablet is helping to avoid the need for urgent hospitalization in high-risk patients during the ongoing COVID-19 outbreak. The acute graft versus host disease (GvHD) treatment market is slated to clock a favorable CAGR of 8.6% during the forecast period. However, the high prevalence of steroid resistance has been found in GvHD patients. Hence, companies in the acute graft versus host disease (GvHD) treatment market should boost their production for ruxolitinib, which helps to improve outcomes in patient with steroid-refractory aGvHD after the allogeneic hematopoietic stem cell transplantation. As such, the acute graft versus host disease (GvHD) treatment market is expected to reach US$ 634.3 Mn by 2031.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Overview

  • This report analyzes the current and future prospects of the global acute graft versus host disease (GvHD) treatment market. Focus on research & development and growth of the pharmaceutical industry are the key factors projected to fuel the growth of the global acute graft versus host disease (GvHD) treatment market during the forecast period.
  • The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global acute graft versus host disease (GvHD) treatment market. The report also provides information and data analysis of the global acute graft versus host disease (GvHD) treatment market about segments based on drug class, route of administration, distribution channel, and region.
  • The overview section of the report provides detailed qualitative analysis of drivers and restraints affecting the global acute graft versus host disease (GvHD) treatment market, along with opportunities in the global market
  • Additionally, the global acute graft versus host disease (GvHD) treatment market report includes company profiles and competitive matrix, which provide data about their businesses, product portfolios, and competitive landscape in the global acute graft versus host disease (GvHD) treatment market
  • The report includes data analysis on the global acute graft versus host disease (GvHD) treatment market attractiveness by region and segments
  • The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the global acute graft versus host disease (GvHD) treatment market. It elaborates on the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute graft versus host disease (GvHD) treatment market.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Key Segments

  • In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others
  • Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous
  • In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is likely to dominate the global acute graft versus host disease (GvHD) treatment market during the forecast period.
  • The market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year.

Acute Graft Versus Host Disease (GvHD) Treatment Market: Regional Outlook

  • In terms of region, the global acute graft versus host disease (GvHD) treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
  • The report provides market size and forecast for each region and country/sub-region from 2017 to 2031. Compound annual growth rate (CAGR) of each of these regions and countries have also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year. The acute graft versus host disease (GvHD) treatment market study also covers the competitive scenario in these regions.

Companies Mentioned in Report

  • Key players in the global acute graft versus host disease (GvHD) treatment market have been profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global acute graft versus host disease (GvHD) treatment market report are
    • Bristol-Myers Squibb
    • Novartis AG
    • Mesoblast Ltd.
    • Equillium, Inc.
    • Cynata Therapeutics Limited
    • MaaT Pharma
    • Incyte Corporation
    • Xenikos B.V.
    • Merck & Co. (OncoImmune, Inc.)
    • medac GmbH
    • CSL Limited

Acute Graft Versus Host Disease (GvHD) Treatment Market – Segmentation

Drug Class
  • Corticosteroids
  • Immunosuppressive Agents
  • Biological Therapy
  • Kinase Inhibitors
  • Monoclonal Antibody
  • Mesenchymal Stem Cell (MSC)
  • Others
Route of Administration
  • Oral
  • Topical
  • Intravenous
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Acute Graft Versus Host Disease [GvHD] Treatment Market Insights, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of acute graft versus host disease treatment market?

Acute graft versus host disease treatment market is expected to reach US$ 634.3 Mn by 2031

What is the anticipated CAGR of the acute graft versus host disease treatment market in the forecast period?

Acute graft versus host disease treatment market is slated to clock a favorable CAGR of 8.6% during 2021-2031

What are the key driving factors for the growth of the acute graft versus host disease treatment market?

Acute graft versus host disease treatment market is driven by rise in focus on introducing novel effective therapeutics to address the unmet medical needs

Which region is expected to project the highest market share in the global acute graft versus host disease treatment market?

North America accounted for a major share of the global acute graft versus host disease (GvHD) treatment market during the forecast period

Who are the key players in the acute graft versus host disease treatment market?

Key players in the global acute graft versus host disease treatment market include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd., Equillium, Inc., Cynata Therapeutics Limited

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Graft Versus Host Disease (GvHD) Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definitions

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

    5.2. Key Industry Events

    5.3. Pipeline Analysis

    5.4. Overview of Companies Offering stem cell treatment and/or Treg cell treatment for Acute Graft Versus Host Disease (GvHD)

    5.5. Treatment and Management of Acute Graft Versus Host Disease (aGvHD)

6. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Corticosteroids

        6.3.2. Immunosuppressive Agents

        6.3.3. Biological Therapy

        6.3.4. Kinase Inhibitors

        6.3.5. Monoclonal Antibody

        6.3.6. Mesenchymal Stem Cell (MSC)

        6.3.7. Others

    6.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class

7. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Oral

        7.3.2. Topical

        7.3.3. Intravenous

    7.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration

8. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Region

10. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. Corticosteroids

        10.2.2. Immunosuppressive Agents

        10.2.3. Biological Therapy

        10.2.4. Kinase Inhibitor

        10.2.5. Monoclonal Antibody

        10.2.6. Mesenchymal Stem Cell (MSC)

        10.2.7. Others

    10.3. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        10.3.1. Oral

        10.3.2. Topical

        10.3.3. Intravenous

    10.4. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. Corticosteroids

        11.2.2. Immunosuppressive Agents

        11.2.3. Biological Therapy

        11.2.4. Kinase Inhibitors

        11.2.5. Monoclonal Antibody

        11.2.6. Mesenchymal Stem Cell (MSC)

        11.2.7. Others

    11.3. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Oral

        11.3.2. Topical

        11.3.3. Intravenous

    11.4. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. Corticosteroids

        12.2.2. Immunosuppressive Agents

        12.2.3. Biological Therapy

        12.2.4. Kinase Inhibitors

        12.2.5. Monoclonal Antibody

        12.2.6. Mesenchymal Stem Cell (MSC)

        12.2.7. Others

    12.3. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Oral

        12.3.2. Topical

        12.3.3. Intravenous

    12.4. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. Japan

        12.5.2. China

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. Corticosteroids

        13.2.2. Immunosuppressive Agents

        13.2.3. Biological Therapy

        13.2.4. Kinase Inhibitors

        13.2.5. Monoclonal Antibody

        13.2.6. Mesenchymal Stem Cell (MSC)

        13.2.7. Others

    13.3. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Oral

        13.3.2. Topical

        13.3.3. Intravenous

    13.4. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. Corticosteroids

        14.2.2. Immunosuppressive Agents

        14.2.3. Biological Therapy

        14.2.4. Kinase Inhibitors

        14.2.5. Monoclonal Antibody

        14.2.6. Mesenchymal Stem Cell (MSC)

        14.2.7. Others

    14.3. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Oral

        14.3.2. Topical

        14.3.3. Intravenous

    14.4. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Ranking, by Company, 2020

    15.3. Company Profiles

        15.3.1. Bristol-Myers Squibb

            15.3.1.1. Company Description

            15.3.1.2. Business Overview

            15.3.1.3. Strategic Overview

            15.3.1.4. SWOT Analysis

        15.3.2. Novartis AG

            15.3.2.1. Company Description

            15.3.2.2. Business Overview

            15.3.2.3. Strategic Overview

            15.3.2.4. SWOT Analysis

        15.3.3. Mesoblast Ltd

            15.3.3.1. Company Description

            15.3.3.2. Business Overview

            15.3.3.3. Strategic Overview

            15.3.3.4. SWOT Analysis

        15.3.4. Equillium, Inc.

            15.3.4.1. Company Description

            15.3.4.2. Strategic Overview

            15.3.4.3. SWOT Analysis

        15.3.5. Cynata Therapeutics Limited

            15.3.5.1. Company Description

            15.3.5.2. Business Overview

            15.3.5.3. Strategic Overview

            15.3.5.4. SWOT Analysis

        15.3.6. MaaT Pharma

            15.3.6.1. Company Description

            15.3.6.2. Strategic Overview

            15.3.6.3. SWOT Analysis

        15.3.7. Incyte Corporation

            15.3.7.1. Company Description

            15.3.7.2. Business Overview

            15.3.7.3. Strategic Overview

            15.3.7.4. SWOT Analysis

        15.3.8. Xenikos B.V.

            15.3.8.1. Company Description

            15.3.8.2. Strategic Overview

            15.3.8.3. SWOT Analysis

        15.3.9. Merck & Co. (OncoImmune, Inc.)

            15.3.9.1. Company Description

            15.3.9.2. Business Overview

            15.3.9.3. Strategic Overview

            15.3.9.4. SWOT Analysis

        15.3.10. medac GmbH

            15.3.10.1. Company Description

            15.3.10.2. SWOT Analysis

        15.3.11. CSL Limited

            15.3.11.1. Company Description

            15.3.11.2. Business Overview

            15.3.11.3. SWOT Analysis

List of Tables

Table 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (1/2)

Table 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (2/2)

Table 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 08: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 09: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 12: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 13: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 14: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 16: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 17: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 19: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 20: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 21: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 22: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 24: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Drug Class, 2020

Figure 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Route of Administration, 2020

Figure 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Distribution Channel, 2020

Figure 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Region, 2020

Figure 06: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 07: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 08: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2031

Figure 09: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Immunosuppressive Agents, 2017–2031

Figure 10: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Biological Therapy, 2017–2031

Figure 11: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Kinase Inhibitors, 2017–2031

Figure 12: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Monoclonal Antibody, 2017–2031

Figure 13: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Mesenchymal Stem Cell, 2017–2031

Figure 14: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Others, 2017–2031

Figure 15: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 16: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 17: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Oral, 2017–2031

Figure 18: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Topical, 2017–2031

Figure 19: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Intravenous, 2017–2031

Figure 20: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 21: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 22: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 23: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 24: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

Figure 25: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Region, 2020 and 2031

Figure 26: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Region, 2021–2031

Figure 27: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 28: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country, 2020 and 2031

Figure 29: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country, 2021–2031

Figure 30: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 31: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 32: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 33: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 34: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 35: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 36: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 38: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 39: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 40: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 41: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 42: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 43: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 44: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 45: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 46: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 47: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 48: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 49: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 50: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 51: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 52: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 53: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 54: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 55: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 56: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 57: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 58: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 59: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 60: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 61: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 62: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 63: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 64: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 65: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 66: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031

Figure 67: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 68: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 69: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 70: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 71: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 72: Market Position Analysis, by Tier and Size of Company

Figure 73: Bristol-Myers Squibb Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020

Figure 74: Bristol-Myers Squibb Breakdown of Net Sales (%), by Region/Country, 2020

Figure 75: Bristol-Myers Squibb R&D Expenses (US$ Mn) 2017–2020

Figure 76: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 77: Novartis AG Breakdown of Net Sales (%), by Region/Country, 2020

Figure 78: Novartis AG Revenue Breakdown of Net Sales (%), by Business Segment, 2020

Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 80: Mesoblast Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 81: Mesoblast Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 82: Cynata Therapeutics Limited Business Overview

Figure 83: Incyte Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 84: Incyte Corporation JAKAFI Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 85: Incyte Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 86: Merck & Co. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 87: Merck & Co. Breakdown of Net Sales (%), by Region/Country, 2020

Figure 88: Merck & Co. Revenue Breakdown of Net Sales (%), by Business Segment, 2020

Figure 89: Merck & Co. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 90: CSL Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 91: CSL Limited Breakdown of Net Sales (%), by Region/Country, 2020

Figure 92: CSL Limited Revenue Breakdown of Net Sales (%), by Business Segment, 2020

Figure 93: CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020 

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

264

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved